sorrento
announces
discovery
small
molecule
strongly
inhibits
infection
preclinical
studies
highlights
place
potential
therapy
strategy
preclinical
studies
small
molecule
demonstrated
potent
viral
load
reduction
log
infection
model
normal
healthy
vero
cells
displays
novel
mechanism
inhibition
potential
additive
benefits
used
therapy
approach
potentially
administered
orally
alone
tested
combination
sorrento
potent
affinity
matured
neutralizing
antibodies
san
diego
globe
newswire
sorrento
therapeutics
nasdaq
srne
sorrento
announced
today
discovered
small
molecule
termed
demonstrated
potent
log
reduction
virus
infection
vitro
virus
infection
experiment
since
beginning
pandemic
sorrento
developed
program
targeting
entire
continuum
care
prevention
early
treatment
rescue
therapies
manage
disease
sorrento
belief
therapies
naturally
follow
approval
effective
single
therapies
regardless
individual
drug
potential
using
drug
repurposing
strategy
sorrento
looking
compounds
could
synergistically
supplement
current
antibody
program
process
screened
collection
salicylanilide
compounds
interest
library
molecules
developed
upon
chemical
scaffolding
known
salicylanilides
preliminary
preclinical
experiments
comparative
data
generated
thus
far
demonstrates
may
effective
another
salicylanilide
niclosamide
small
molecule
previously
used
treat
tapeworm
infection
recently
entered
clinical
trials
examine
effectiveness
drug
repurposing
diseases
gained
widespread
attention
recent
years
several
drugs
approved
fda
moreover
global
emergency
pandemic
one
strategies
implemented
major
pharma
academic
efforts
sorrento
intent
examining
salicylanilide
library
starting
point
targeting
potentially
coronaviruses
grounded
upon
concept
drug
repurposing
generally
cost
time
effective
potential
high
returns
relatively
low
risk
sorrento
unique
approach
goes
beyond
identifying
drug
repurposed
molecule
screening
aimed
finding
optimal
small
molecule
candidate
could
developed
potential
enhance
proprietary
pipeline
clinical
stage
neutralizing
antibodies
developed
initially
therapy
potentially
reduce
viral
load
severely
affected
patients
parallel
potential
combination
sorrento
antibodies
currently
development
validated
synergistic
efficacy
also
ensure
safety
combination
therapy
established
prior
human
trials
henry
ji
sorrento
chairman
ceo
stated
shown
exceptional
therapeutic
potential
orally
available
greater
systemic
exposure
besides
potent
salicylanilide
niclosamides
preclinical
trials
date
see
high
potential
value
new
small
molecule
inhibitor
either
standalone
therapeutic
used
conjunction
proprietary
neutralizing
antibodies
nabs
affinity
matured
developed
company
ultimate
goal
able
provide
patients
solutions
stage
disease
continuum
ensure
therapeutic
solutions
put
forward
work
well
together
enhance
sorrento
therapeutics
sorrento
clinical
stage
biopharmaceutical
company
developing
new
therapies
treat
cancers
sorrento
multimodal
multipronged
approach
fighting
cancer
made
possible
extensive
platforms
including
key
assets
fully
human
antibodies
library
clinical
stage
therapies
conjugates
adcs
clinical
stage
oncolytic
virus
sorrento
also
developing
potential
antiviral
therapies
vaccines
coronaviruses
including
diagnostic
test
solutions
including
sorrento
commitment
therapies
patients
also
demonstrated
effort
advance
agonist
pain
management
small
molecule
resiniferatoxin
rtx
lidocaine
topical
system
treatment
neuralgia
rtx
completed
phase
trial
intractable
pain
associated
cancer
phase
trial
osteoarthritis
patients
approved
fda
february
information
visit
statements
press
release
statements
made
presentation
meeting
contain
statements
related
sorrento
therapeutics
safe
harbor
provisions
section
private
securities
litigation
reform
act
subject
risks
uncertainties
could
cause
actual
results
differ
materially
projected
statements
include
statements
regarding
sorrento
pipeline
plans
respect
clinical
programs
including
potential
used
standalone
therapeutic
therapy
treatment
potential
method
administration
belief
therapies
naturally
follow
approval
effective
single
therapies
potency
potency
relative
salicylanilide
niclosamides
time
efficiencies
associated
drug
repurposing
well
potential
high
returns
relatively
low
risk
associated
therewith
potential
work
together
enhance
potential
reduce
viral
load
sorrento
therapeutic
diagnostic
product
candidates
pipeline
goals
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
expressed
statements
include
limited
risks
related
sorrento
subsidiaries
affiliates
partners
technologies
prospects
collaborations
including
limited
clinical
development
risks
including
risks
progress
timing
cost
results
clinical
trials
product
development
programs
risk
difficulties
delays
obtaining
regulatory
approvals
risks
clinical
study
results
may
meet
endpoints
clinical
study
data
generated
studies
may
support
regulatory
submission
approval
risks
prior
test
study
trial
results
may
replicated
future
studies
trials
risks
manufacturing
supplying
drug
product
risks
related
leveraging
expertise
employees
subsidiaries
affiliates
partners
assist
company
execution
therapeutic
diagnostic
product
candidates
strategies
risks
related
global
impact
risks
described
sorrento
recent
periodic
reports
filed
securities
exchange
commission
including
sorrento
annual
report
form
year
ended
december
subsequent
quarterly
reports
form
filed
securities
exchange
commission
including
risk
factors
set
forth
filings
investors
cautioned
place
undue
reliance
statements
speak
date
release
undertake
obligation
update
statement
press
release
except
required
law
contact
alexis
nahama
dvm
svp
corporate
development
email
mediarelations
sorrento
logo
registered
trademarks
sorrento
therapeutics
trademarks
sorrento
therapeutics
trademark
owned
scilex
pharmaceuticals
trademarks
property
respective
owners
sorrento
therapeutics
rights
reserved
